CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Hangzhou Diagens Biotechnology Co., Ltd./ADR (HGZDY) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Hangzhou Diagens Biotechnology Co., Ltd./ADR (HGZDY)

Biotechnology · market cap —

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2027-10-31 (est.)
PDUFA
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Not yet
generate it
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
The catalyst path
  • 2027-10-31 (est.)PDUFA · Picankibartimp 8/10
Pipeline
AssetPhaseIndication
PicankibartPhase 3Psoriatic Arthritis
IBI112Phase 3Psoriasis

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for HGZDY (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.